This week's FierceBiotech is brought to you by Rho, Inc.

Trouble viewing? Click here.


5469c2bcec492af9843284ede37d6326.jpg

Hi E,

Recruitment and enrollment is the core of a successful clinical trial. But are we truly serving the population we strive to heal? What can we do better to ensure that our trials are an accurate reflection of the people who need the medicine we are testing?

Rho experts, Yael Symes, PhD, MSP, Integrated Product Development Associate and Jack Modell, MD, Vice President and Senior Medical Officer share their knowledge and research on improving diversity in clinical trials in their article, "What Drug Development Sponsors, Contract Research Organizations, and Investigators Can Do to Increase Diversity in Clinical Trials" in the recently published October issue of The Journal of Clinical Pharmacology. It illuminates who is participating in clinical trials and why, in addition to exploring why diversity in clinical research is important for ethical, scientific, and financial reasons. As Dr. Symes states, “Recruiting diverse clinical trial populations is good science.”

Contact us today to learn more about how you can improve diversity in your upcoming studies. If you missed our webinar on the topic, you can download it here

View Presentation

Want to reach 137,000+ FierceBiotech subscribers with your own message?
Contact [email protected] or call 202-824-5074.



You are currently subscribed as [email protected].
If you no longer wish to receive communications from FierceBiotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

FierceMarkets, a division of Questex, LLC
1900 L St. NW Suite 400 
Washington, DC 20036